UK-based biotech Avacta Group plc plans to action its proprietary Affimer and pre|CISION platforms in a wide range of disease areas – creating products that are easier to manufacture than traditional antibody therapies.
Avacta Pursues Combination Therapy Approach Targeting Solid Tumors
Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.
